Kymera Therapeutics

About Kymera Therapeutics

Kymera Therapeutics is dedicated to advancing cutting-edge science to develop a new generation of medicines that address critical health problems and improve patients' lives by targeting the fundamental drivers of disease through targeted protein degradation.

Products & Services

Pipeline of Therapeutics:A pipeline of first-in-class therapeutics designed to transform the standard of care for patients, driven by a powerful drug discovery engine.

KT-621 (Oral STAT6 Degrader):A first-in-class oral medicine for immunology, with positive first-in-human results from a Phase 1 clinical trial.

KT-579 (IBD)

Specialties

Targeted Protein Degradation Immunology Oral Medicines Drug Discovery Engine Targeted protein degradation Drug discovery First-in-class therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 602000000 MR: - FA: $602.0 million FAN: 602000000	D: 2025-12-11 FD: 2025-12-11	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 602000000 MR: - FA: $602.0 million FAN: 602000000	D: 2025-12-09 FD: 2025-12-09	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 500000000 MR: - FA: $500.0 million FAN: 500000000	D: 2025-12-08 FD: 2025-12-08	6 investors
4	RT: Public Offering T: - FT: Public Offering	A: 250800000 MR: - FA: $250.8 million FAN: 250800000	D: 2025-06-26 FD: 2025-06-26	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-06-25 FD: 2025-06-25	5 investors
6	RT: Public Offering T: - FT: Public Offering	A: 225000000 MR: - FA: $225 million FAN: 225000000	D: 2024-08-21 FD: 2024-08-21	4 investors
7	RT: Public Offering T: - FT: Public Offering	A: 225000000 MR: - FA: $225 million FAN: 225000000	D: 2024-08-19 FD: 2024-08-19	4 investors
8	RT: Public Offering T: - FT: Public Offering	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2024-01-09 FD: 2024-01-09	4 investors
9	RT: Public Offering T: - FT: Public Offering	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2024-01-05 FD: 2024-01-05	4 investors
10	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2024-01-04 FD: 2024-01-04	3 investors

Public Offering Latest

2025-12-11

$602.0M

6 investors (Pro only)

Public Offering 2025-12-09

$602.0M

Public Offering 2025-12-08

$500.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nello Mainolfi

Founder, President and CEO

N

Noah Goodman

Chief Business Officer

J

Juliet Williams

Head of Research

N

Nello Mainolfi

Founder, President & CEO

B

Brian Adams

Chief Legal Officer and Corporate Secretary

J

Jeremy Chadwick

Chief Operating Officer

View 9 more team members with Pro

Unlock Full Team Directory

Recent News